Trial Profile
KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Surgical blood loss
- Focus Therapeutic Use
- Acronyms KALAHARI-1
- Sponsors Cubist Pharmaceuticals; Dyax
- 05 Jun 2014 New trial record